Across TCGA pan-cancer cohorts, SH2D5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SH2D5 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SH2D5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH2D5 expression acts as an unfavorable survival marker.
BLCA, UCEC, and SKCM are the cancer types where SH2D5 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.